Seyedeh Noushin Zahedi1, Seyed Hossein Hejazi2, Maryam Boshtam3, Farahnaz Amini4, Hossein Fazeli5, Mahdieh Sarmadi1, Mahsa Rahimi1, Hossein Khanahmad6. 1. Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Hezarjerib Street, 8174643446, Isfahan, Iran. 2. Department of Parasitology and Mycology, Skin Diseases and Leishmaniasis Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. 3. Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. 4. Faculty of Medicine and Health Sciences, School of Healthy Aging, Medical Aesthetics and Regenerative Medicine, UCSI University, Kuala Lumpur, Malaysia. 5. Department of Bacteriology and Virology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. 6. Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Hezarjerib Street, 8174643446, Isfahan, Iran. h_khanahmad@med.mui.ac.ir.
Abstract
PURPOSE: Leishmaniasis, a widespread parasitic disease, is a public health concern that is endemic in more than 90 countries. Owing to the drug resistance and also undesirable complications, designing new therapeutic methods are essential. C-reactive protein (CRP) is an acute phase protein of plasma with several immune modulatory functions. This study aimed to evaluate the effect of human recombinant CRP (hrCRP) on treating cutaneous leishmaniasis in mice models. METHODS: hrCRP was expressed in E. coli Rosetta-gami and extracted from the SDS-PAGE gel. Male BALB/c mice were inoculated subcutaneously at the base of their tails by 1 × 105 stationary-phase of Leishmania major promastigotes (MHRO/IR/75/ER) suspended in sterile phosphate buffered saline (PBS). Nodules and subsequently, ulcers developed 14 days post-injection. 1.5 µg of the purified protein was administered on lesions of pre-infected mice by Leishmania major in the intervention group for five consecutive days. RESULTS: The mean area of the lesions was decreased by about seven folds in the intervention group as compared to the control group after two weeks of the treatment (p = 0.024). The results were verified by the real-time polymerase chain reaction so that the parasite burden was determined 27 times in the control group as compared to the intervention group (p = 0.02). Two weeks after treatment, the conversion of the lesions to scars in the intervention group was observed. CONCLUSION: The results indicate a potential therapeutic role for hrCRP in improving cutaneous leishmaniasis due to Leishmania major in mice models. The healing was in a stage-dependent manner.
PURPOSE:Leishmaniasis, a widespread parasitic disease, is a public health concern that is endemic in more than 90 countries. Owing to the drug resistance and also undesirable complications, designing new therapeutic methods are essential. C-reactive protein (CRP) is an acute phase protein of plasma with several immune modulatory functions. This study aimed to evaluate the effect of human recombinant CRP (hrCRP) on treating cutaneous leishmaniasis in mice models. METHODS: hrCRP was expressed in E. coli Rosetta-gami and extracted from the SDS-PAGE gel. Male BALB/c mice were inoculated subcutaneously at the base of their tails by 1 × 105 stationary-phase of Leishmania major promastigotes (MHRO/IR/75/ER) suspended in sterile phosphate buffered saline (PBS). Nodules and subsequently, ulcers developed 14 days post-injection. 1.5 µg of the purified protein was administered on lesions of pre-infectedmice by Leishmania major in the intervention group for five consecutive days. RESULTS: The mean area of the lesions was decreased by about seven folds in the intervention group as compared to the control group after two weeks of the treatment (p = 0.024). The results were verified by the real-time polymerase chain reaction so that the parasite burden was determined 27 times in the control group as compared to the intervention group (p = 0.02). Two weeks after treatment, the conversion of the lesions to scars in the intervention group was observed. CONCLUSION: The results indicate a potential therapeutic role for hrCRP in improving cutaneous leishmaniasis due to Leishmania major in mice models. The healing was in a stage-dependent manner.
Entities:
Keywords:
C-reactive protein; Cutaneous leishmaniasis; Leishmania major; Recombinant protein
Authors: Sergio M Borghi; Victor Fattori; Ivete Conchon-Costa; Phileno Pinge-Filho; Wander R Pavanelli; Waldiceu A Verri Journal: Parasitol Res Date: 2016-12-09 Impact factor: 2.289
Authors: Rory C F De Brito; Jamille M De O Cardoso; Levi E S Reis; Joao F Vieira; Fernando A S Mathias; Bruno M Roatt; Rodrigo Dian D O Aguiar-Soares; Jeronimo C Ruiz; Daniela de M Resende; Alexandre B Reis Journal: Front Immunol Date: 2018-05-11 Impact factor: 7.561